Loading
Invivyd, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 20 Nov 2025.
Invivyd, Inc.: what insiders have been doing
This page follows insider dealings at Invivyd, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Over the twelve months to 18 October 2026, 26 filings were filed, from 11 insiders.
On the market, 1 insider bought (1 purchase totalling €108k) while 5 insiders sold (10 sales totalling €153k). The net balance comes to €45k on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The largest single trade was a purchase of €108k by Mclaughlin Kevin F, published on 20 November 2025. Those buying include 1 senior executive.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 26 filings here. Over the whole record (from 2021), the tally stands at 3 purchases and 21 sales.
The last insider purchase was made public on 20 November 2025, 332 days ago. Typically, a trade is published a median of 3 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
51
Thresholds
n/a
Buy Volume
€4M
3 ops. · all time
Sell Volume
€19M
21 ops. · all time
Who traded when
BuySaleMcguire Terrance5 sales
Jill Andersen4 sales
Robert D. Allen III4 sales
Julie Green2 sales
Timothy Edward Lee2 sales
William E. Duke2 sales
+1 other insider
Since the insiders bought
- -75.3%Entry US$2.50 · Close 16 Oct 2026 US$0.62
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,134 of 24,158 companies
20.4
score / 100
Value8
Quality33
FCF yld-30%
Earn yld-27%
EV/EBITDA·
ROE-96%
Gross mgn93%
Net mgn-98%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.67
Analyst consensus
3 analysts1.00/5
US$10.00Target US$10.00(+1395%)US$10.00
Income statement
RevenueUS$53.4M
Gross profitUS$49.7M93% margin
EBITDA-US$53.5M-100% margin
Net income-US$52.5M-183.9% margin
Valuation
PER (forward)-1.2x
P/Book1.1x
Beta0.95
Balance sheet & cash
Market capUS$197.1M
Total debtUS$2.5M
Free Cash Flow-US$58.3M
Debt / Equity5%
Profitability & ownership
ROE-95.9%
ROA-45.7%
% insiders7.2%
% institutions86.9%
Last declaration on 18 August 2026
Declarations51 total
102,000 sharesCommon StockSEC:0001193125-26-355913:0
22,355 shares@ US$0.7220.0058% mcap26.4% of flowCommon StockSEC:0001193125-26-355913:1
102,000 sharesCommon StockSEC:0001193125-26-355914:0
102,000 sharesCommon StockSEC:0001193125-26-355915:0
22,355 shares@ US$0.7220.0058% mcap26.4% of flowCommon StockSEC:0001193125-26-355915:1
18,425 shares@ US$0.84290.0055% mcap25.4% of flowCommon StockSEC:0001193125-26-355915:2
102,000 sharesCommon StockSEC:0001193125-26-355911:0
170,000 sharesCommon StockSEC:0001193125-26-355912:0
18,425 shares@ US$0.84290.0055% mcap25.4% of flowCommon StockSEC:0001193125-26-355913:2
22,355 shares@ US$0.7220.0058% mcap26.4% of flowCommon StockSEC:0001193125-26-355914:1
20,679 shares@ US$0.7220.0053% mcap17.8% of flowCommon StockSEC:0001193125-26-355911:1
17,043 shares@ US$0.84290.0051% mcap17.1% of flowCommon StockSEC:0001193125-26-355911:2
37,256 shares@ US$0.7220.0096% mcap17.8% of flowCommon StockSEC:0001193125-26-355912:1
30,706 shares@ US$0.84290.0092% mcap17.1% of flowCommon StockSEC:0001193125-26-355912:2
18,425 shares@ US$0.84290.0055% mcap25.4% of flowCommon StockSEC:0001193125-26-355914:2
40,800 shares@ US$0.72090.010% mcap48.2% of flowCommon StockSEC144:0001193125-26-354034
40,800 shares@ US$0.72090.010% mcap48.2% of flowCommon StockSEC144:0001193125-26-354036
37,741 shares@ US$0.72090.0097% mcap32.4% of flowCommon StockSEC144:0001193125-26-354030
68,001 shares@ US$0.72090.017% mcap32.4% of flowCommon StockSEC144:0001193125-26-354032
40,800 shares@ US$0.72090.010% mcap48.2% of flowCommon StockSEC144:0001193125-26-354033
99,000 sharesCommon StockSEC:0001193125-26-057828:0
165,000 sharesCommon StockSEC:0001193125-26-057814:0
99,000 sharesCommon StockSEC:0001193125-26-057815:0
99,000 sharesCommon StockSEC:0001193125-26-057819:0
99,000 sharesCommon StockSEC:0001193125-26-057822:0
25 of 51 declarations
About Invivyd, Inc.
Invivyd, Inc. (ticker: IVVD) is a US-listed biopharmaceutical company traded on the NASDAQ market in the United States. The company focuses on preventing serious viral infectious diseases through monoclonal antibodies, with a strategy built around viral surveillance, predictive modeling, and advanced antibody engineering. From an equity-research standpoint, Invivyd fits the profile of a specialty biotech rather than a broad platform company: its valuation is driven by clinical data, regulatory outcomes, product uptake, and the durability of its authorized assets.
The company was built around a proprietary antibody-discovery and optimization approach and has historically centered its efforts on COVID-19, while also describing an ambition to expand into other high-need viral indications such as influenza. Invivyd’s INVYMAB™ platform combines state-of-the-art viral surveillance with modeling tools intended to identify and engineer antibodies that can keep pace with rapidly evolving viral threats. The business is headquartered in the United States, and its operating model is consistent with a small-cap US biotech that relies on a lean commercial organization and external regulatory milestones rather than scale manufacturing breadth.
Read moreShow less
Its lead commercial product is PEMGARDA® (pemivibart), a monoclonal antibody used for prophylaxis in selected immunocompromised populations at risk from SARS-CoV-2. The pipeline also includes next-generation candidates such as VYD2311, which management has positioned as a potentially low-dose, intramuscular, scalable and longer-lasting option. Invivyd is therefore competing in a narrow but meaningful niche: protection for vulnerable patients where standard vaccination may be insufficient. Its competitive position depends less on mass-market demand and more on maintaining a differentiated profile versus other antiviral and antibody-based developers, while navigating payer coverage, physician adoption, and variant evolution.
Recent company updates suggest improving commercial traction. In 2025, Invivyd reported rising PEMGARDA product revenue and highlighted continued field-force execution with broader specialty reach. The company also disclosed neutralizing activity data for PEMGARDA and VYD2311 against dominant SARS-CoV-2 variants, reinforcing the relevance of its variant-response strategy. In addition, Invivyd has advanced clinical work such as the DECLARATION program, underscoring that the story remains a mix of early commercial execution and ongoing development risk.
For investors in France, Belgium, and Switzerland, the key point is that Invivyd is a high-beta biotech exposure on NASDAQ in the United States: upside can be significant if commercialization and clinical expansion continue, but the name remains highly sensitive to FDA authorization status, reimbursement, competitive pressure, and cash-burn dynamics. In the context of SEC Form 4 insider transactions, insider activity should be interpreted as secondary to these core fundamentals.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
